How does PCSK9 affect LDL cholesterol levels?

PCSK9, or proprotein convertase subtilisin/kexin type 9, is a protein that plays a crucial role in regulating LDL cholesterol levels in the body. PCSK9 acts by binding to LDL receptors and promoting their degradation, preventing them from recycling back to the cell surface. This leads to a reduction in the number of LDL receptors available to clear LDL cholesterol from the bloodstream. As a result, LDL cholesterol levels increase since there are fewer receptors to take it up from the blood. Inhibiting PCSK9 with medications, such as monoclonal antibodies, can prevent the binding and degradation of LDL receptors, allowing them to recycle and effectively lower LDL cholesterol levels. This medication is especially useful for individuals with high LDL cholesterol or those who do not respond sufficiently to other cholesterol-lowering treatments.

This mind map was published on 19 December 2023 and has been viewed 102 times.